Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) Short Interest Update

Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) experienced a notable decrease in short interest throughout December. As of December 15th, the total short interest amounted to 19,000 shares. This represents a decline of 5.9% compared to the 20,200 shares reported on November 30th. Considering the average trading volume of 19,600 shares, the current days-to-cover ratio is 1.0 days, indicating that approximately 0.6% of the company's shares are sold short.

Institutional Trading of Cryo-Cell International

Recently, an institutional investor increased its stake in Cryo-Cell International. Geode Capital Management LLC raised its ownership by 68.5% during the third quarter, according to its latest report filed with the Securities and Exchange Commission (SEC). Following this increase, the fund held 39,860 shares of Cryo-Cell stock after acquiring an additional 16,203 shares in the quarter. As per the latest SEC filing, Geode Capital Management LLC represented about 0.49% ownership of Cryo-Cell International, valued at $254,000. Overall, institutional investors own roughly 10.44% of the stock.

Cryo-Cell International Trading Up Slightly

During midday trading on Wednesday, shares of NYSEAMERICAN:CCEL rose by 0.1%, reaching $7.41. A total of 9,303 shares changed hands, which is lower than the average volume of 11,188. Cryo-Cell International currently holds a market capitalization of $59.72 million, with a price-to-earnings ratio of -6.99, and a beta of 0.49. The stock has shown a 52-week low of $4.47 and a 52-week high of $9.50.

Cryo-Cell International last released its earnings results on October 15th, reporting earnings per share of $0.13, exceeding the consensus estimate of $0.02 by $0.11. For that quarter, the company recorded revenues totaling $8.07 million. However, Cryo-Cell reported a negative return on equity of 42.06% along with a negative net margin of 28.03%.

Cryo-Cell International Dividend Announcement

The company also disclosed a dividend, which was paid on November 29th. For investors on record as of November 15th, a dividend of $0.25 per share was distributed. The ex-dividend date coincided with November 15th. Cryo-Cell International’s current payout ratio is -94.34%.

Overview of Cryo-Cell International

Cryo-Cell International, Inc. specializes in cellular processing and cryogenic storage, particularly focusing on the collection and preservation of umbilical cord blood stem cells for family use. The company also offers cord tissue services, which involve storing parts of the umbilical cord tissue. This tissue contains mesenchymal stem cells, utilized in regenerative medicine for various medical conditions, including heart and kidney diseases, ALS, wound healing, autoimmune diseases, multiple sclerosis, Alzheimer's disease, and Parkinson's disease.

Cryo-Cell, ShortInterest, InstitutionalInvestors